← Evidence map

ArticleClinical and molecular hepatology2026

Targeting the ASB3-CPT1A axis-a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on "Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyltransferase 1A".

Yueying Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Targeting the ASB3-CPT1A axis-a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on "Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyltransferase 1A". | Socratic